Cormedix Inc. Form 8-K Summary
Business Context and Reporting Period
Company: Cormedix Inc.
Filing Date: October 17, 2013
Reporting Period: Current Report (Event Date: October 17, 2013)
Business Context: The company entered into material definitive agreements to raise capital through the sale of preferred stock and warrants to existing institutional investors. Proceeds are intended for general corporate purposes, specifically the development and commercialization of Neutrolin, working capital, and capital expenditures.
Key Financial Metrics and Transaction Details
This filing reports a specific financing transaction rather than periodic financial performance metrics (revenue, profit, cash flow). Key transaction figures include:
- Gross Proceeds: $3,000,000 aggregate.
- Securities Sold:
- 150,000 shares of Series C-1 Non-Voting Convertible Preferred Stock.
- 150,000 shares of Series C-2 Non-Voting Convertible Preferred Stock.
- Warrants to purchase up to 750,000 shares of common stock per investor (1,500,000 total).
- Price: $10.00 per share of Series C Stock (sold together with warrants).
- Conversion Terms: Each Series C share converts into 10 common shares at $1.00 per share (subject to a 9.99% beneficial ownership limitation).
- Warrant Terms: Exercise price of $1.25 per share; exercisable one year after issuance; five-year term (subject to 4.99% or 9.99% beneficial ownership limitations).
- Liquidation Preference: $10.00 per share, senior to common stock and Series B, on parity with Series B, and junior to Series D and E.
Material Changes and Conditions
The filing details a material change in capital structure contingent on specific closing conditions:
- Debt Exchange: Closing requires the exchange of a $400,000 convertible note for Series D Preferred Stock and a $750,000 convertible note for Series E Preferred Stock held by one of the investors.
- Listing Compliance: Closing is conditional upon receiving a letter from the NYSE MKT confirming regained compliance with Section 1003(a)(i) and Section 1003(a)(iv) of the Company Guide.
- Anticipated Closing: On or about October 22, 2013.
Guidance, Outlook, and Risks
Management Commentary: The company intends to use net proceeds for the development and commercialization of Neutrolin, working capital, and capital expenditures. No placement agent or underwriter was involved.
Risks and Contingencies:
- Closing Risk: The transaction is not yet closed and is subject to customary conditions and the specific debt exchange and listing compliance requirements noted above.
- Dilution: Conversion of preferred stock and exercise of warrants will increase the number of common shares outstanding, subject to beneficial ownership limits.
- Regulatory Status: Series C-2 stock and warrants are sold under Section 4(a)(2) exemption and cannot be resold in the U.S. without registration or an exemption.
Financial Metrics: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels outside of the specific notes mentioned for exchange.
Investor Verification Checklist
- Verify the successful exchange of the $400,000 and $750,000 convertible notes for Series D and Series E preferred stock.
- Confirm receipt of the NYSE MKT compliance letter regarding Sections 1003(a)(i) and 1003(a)(iv).
- Review the Certificates of Designation for Series C, D, and E stock filed as exhibits to the post-closing 8-K for complete terms.
- Monitor the filing of the prospectus supplement for Series C-1 stock under Rule 424(b)(5).
- Assess the impact of the 9.99% beneficial ownership limitation on the convertibility of the new preferred shares.